Background Biologic therapy in psoriasis raises concerns regarding COVID‐19 infection risk and vaccine response, yet real‐world data remain limited. Objective To evaluate COVID‐19 infection rates, clinical severity, and vaccination response among biologic‐treated patients with psoriasis during the COVID‐19 pandemic. Methods This cohort study included 12,306 patients with psoriasis followed at a tertiary medical center between March 2020 and May 2023. Primary outcomes included estimated SARS‐CoV‐2 infection rates, hospitalization, ICU admission, mortality, and a composite severe COVID‐19 outcome (hospitalization, ICU admission, or death). Results Based on national seroprevalence‐adjusted rates, infection occurred in 673 of 962 biologic‐treated patients (70.0%) and 7657 of 11,344 nonbiologic patients (67.5%) ( p = 0.18). Hospitalization was more frequent among biologic‐treated patients (45.2% vs 25.1%; p < 0.001), while ICU admission rates were comparable (2.6% vs 2.0%; p = 0.41). Mortality was significantly lower in the biologic group (6.3% vs 12.1%; p < 0.001). Conclusions Biologic therapy in psoriasis was not associated with increased susceptibility to SARS‐CoV‐2 infection or impaired vaccine response.
Bar et al. (Thu,) studied this question.